Pharmacogenetics aspects of oral anticoagulants therapy
نویسندگان
چکیده
RATIONALE Vitamin K antagonists (VKA), such as warfarin and acenocoumarol, are widely used for the prevention and treatment of thromboembolic diseases and they are some of the most commonly prescribed types of medications. They are characterized by narrow therapeutic indices and inter-individual or intra-individual variability in response to the treatment. OBJECTIVE to establish the influence of several genetic factors on VKA efficacy and adverse reactions. METHODS AND RESULTS The metabolism of VKA differs depending on their chemical structure: indandiones derivatives (fluindione) or coumarin derivatives (acenocoumarol, phenprocoumon or warfarin). They are mostly metabolized in hepatocytes via a monooxygenase, cytochrome P450 2C9 (CYP2C9), resulting in inactive products. The gene encoding CYP2C9 is polymorphic, its genetic variants being associated with differences in the enzymatic activity of CYP2C9. The most important in terms of their frequency in the general population are CYP2C9*2 and CYP2C9*3. Both alleles are associated with a marked decrease in CYP2C9 enzyme activity. VK epoxide reductase (VKOR) is an enzyme with an important role in VK metabolism. Various polymorphisms in the VKORC1 gene have been described. VKORC1*2 haplotype seems to be the most important in relation to the variability in response to VKA. DISCUSSIONS Various studies have shown a relationship between the genotype and the mean warfarin maintenance dosing: in patients carrying 2C9*1/*2 alleles, the dose is reduced by 18-40% in patients carrying 2C9*2/*2 alleles, by 21-49% in patients carrying 2C9*1/*3 alleles. The A allele of the c.-1639G>A polymorphism in the VKORC1 gene is associated with the need for a lower dose of acenocoumarol in patients on anticoagulant therapy. ABBREVIATIONS SNP = Single Nucleotide Polymorphism, VKA = vitamin K antagonists, C1 - VKORC1 = vitamin K epoxide reductase complex subunit, INR = International Normalized Ratio.
منابع مشابه
Pharmacogenetics of oral anticoagulant therapy
Introduction In the last 70 years the antagonists of vitamin K (AVK) were the only therapeutic solution for oral anticoagulation in primary and secondary prophylaxis of arterial and venous thrombosis. The utility of AVK was demonstrated in many situations and presently they are taken by millions patients in the entire world. Many clinical and lab studies contributed to understanding of AVKs’ ph...
متن کاملPharmacogenetics of Warfarin
วารสารโลหติวทิยาและเวชศาสตร บรกิารโลหติ ป ที ่ 16 ฉบบัที ่ 3 กรกฎาคม-กนัยายน 2549 Warfarin is the mainstay of anticoagulation therapy. It is used for the prevention and treatment of venous thromboembolism, myocardial infarction, and strokes.1 Its clinical use, however, is complicated by the fact that it has a narrow therapeutic index with associated adverse effects that are potentially serious,...
متن کاملAn Overview of Novel Anticoagulants
Arterial and venous thromboembolism is one of the most common causes of death worldwide. For almost seventy years, heparin, low molecular weight heparin, and vitamin K antagonists have been widely used in the prevention and treatment of thromboembolic disorders. However, many of the limitations of these traditional anticoagulants have led to the search for and attempts to introduce better drug ...
متن کاملUse of genetic data to guide therapy in arterial disease.
There is considerable interindividual variation in the response to antiplatelet and anticoagulant therapies. It has been proposed that this variability in drug response may be attributable to genetic variants. Thus, pharmacogenetics may help to accurately predict response to cardiovascular disease (CVD) therapies in order to maximize drug efficacy, minimize drug toxicity, and to tailor personal...
متن کاملPHARMACOGENETIC VARIATION AT CYP2D6, CYP2C9, AND CYP2C19: Population Genetic and Forensic Aspects
.......................................................................................................................8 REVIEW OF THE LITERATURE...................................................................................10 1 Pharmacogenetics ...........................................................................................................10 2 Drug-Metabolizing Enzymes.............
متن کامل